Novo Nordisk expects the oral version of its semaglutide drug to treat obesity to have similar efficacy as its Wegovy injection, with data from a late-stage clinical trial due before the end of June
COPENHAGEN/LONDON - , a senior executive said on Thursday.
Head of development Martin Holst Lange was discussing the trial called OASIS 1 on a call with analysts following the release of better-than-expected first-quarter results by the Danish drugmaker. He said the final results of the trial for the once-daily pill are not yet available, but based on the data for the same pill to treat diabetes, the company would expect to see similar efficacy and safety to Wegovy.
The company's hugely popular Wegovy therapy is a weekly injection. The treatment belongs to a class of drugs known as GLP-1 agonists originally developed to treat type 2 diabetes. "An oral offering in the obesity space holds a really strong potential," Lange said, adding the company had learned that some patients and prescribing doctors would prefer a pill form of the semaglutide drug over the injection form.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Novo Nordisk cuts some US supply of obesity drug Wegovy to cope with demandDanish drug developer Novo Nordisk said it would have to halve the supply of starter doses of its popular Wegovy weight-loss drug in the United States to cope with high demand after reporting forecast-beating results on Thursday.
Les mer »
Novo Nordisk limits distribution of low doses of Wegovy in U.S.Novo Nordisk is holding back low doses of Wegovy, its recently approved obesity medication, in the U.S. to conserve supplies for patients already using the drug, the company said Thursday.
Les mer »
Breakingviews - Novo Nordisk’s chunky valuation risks crash dietNovo Nordisk’s weighty valuation could be headed for a crash diet. On Thursday, the maker of diabetes and obesity remedies was worth over $270 billion, twice its value only two years ago. But its untarnished bull run may be scuppered by competition from rival Eli Lilly , questions about effectiveness and market size.
Les mer »
Novo Nordisk’s chunky valuation risks crash dietThe $274 bln pharma group trades at a big premium to peers. Investors are buoyed by hopes Novo can take a large share of an obesity market that could be worth $100 bln by 2031. But competition and questions about its drug’s effectiveness could slim down its valuation.
Les mer »
Novo Nordisk rivals see room to compete in $100 billion weight-loss drug marketThe enormous demand for weight-loss treatments like Novo Nordisk’s Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said.
Les mer »
Wegovy weight-loss drug supply to be temporarily curtailed by Novo Nordisk as it ramps up productionNovo Nordisk on Thursday said demand is so strong for its weight loss injectable medicine that it will have to reduce the supply temporarily.
Les mer »